XTL Biopharmaceuticals Ltd Cash Flow Conversion Efficiency
XTL Biopharmaceuticals Ltd cash flow conversion efficiency. Based on the latest financial reports, XTL Biopharmaceuticals Ltd (XTLB) has a cash flow conversion efficiency ratio of -0.083x as of December 2017. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-301.00K ≈ $-806.97 USD) by net assets (ILA3.62 Million ≈ $9.70K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of XTL Biopharmaceuticals Ltd (2013–2024)
Cash flow conversion efficiency of XTL Biopharmaceuticals Ltd from 2013 to 2024. This chart illustrates how XTL Biopharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View XTLB live share price for real-time trading data and today's change.
XTL Biopharmaceuticals Ltd Cash Flow Conversion Ratio Explained
XTL Biopharmaceuticals Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
XTL Biopharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of XTL Biopharmaceuticals Ltd ranked by their cash flow conversion efficiency. Also see XTLB market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Coloseum Holding a.s.
PR:COLOS
|
N/A |
|
N2OFF Inc
NASDAQ:NITO
|
-0.089x |
|
BIOMIND LABS INC.
F:3XI
|
0.025x |
|
Mittal Life Style Limited
NSE:MITTAL
|
0.102x |
|
New Sources Energy N.V
AS:NSE
|
0.001x |
|
60 Degrees Pharmaceuticals, Inc. Common Stock
NASDAQ:SXTP
|
-0.883x |
|
WestKam Gold Corp
V:WKG
|
0.023x |
|
Azitra Inc
NYSE MKT:AZTR
|
-0.761x |
Annual Cash Flow Conversion Efficiency for XTL Biopharmaceuticals Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of XTL Biopharmaceuticals Ltd from 2013 to 2024. Review XTLB free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA5.43 Million ≈ $14.57K |
ILA-1.62 Million ≈ $-4.34K |
-0.298x | +6.52% |
| 2023-12-31 | ILA2.22 Million ≈ $5.95K |
ILA-707.00K ≈ $-1.90K |
-0.318x | -41.35% |
| 2022-12-31 | ILA4.00 Million ≈ $10.72K |
ILA-901.00K ≈ $-2.42K |
-0.225x | -14.54% |
| 2021-12-31 | ILA5.33 Million ≈ $14.30K |
ILA-1.05 Million ≈ $-2.81K |
-0.197x | -44.61% |
| 2020-12-31 | ILA6.25 Million ≈ $16.75K |
ILA-850.00K ≈ $-2.28K |
-0.136x | -4.56% |
| 2019-12-31 | ILA6.98 Million ≈ $18.71K |
ILA-908.00K ≈ $-2.43K |
-0.130x | -32.67% |
| 2018-12-31 | ILA8.32 Million ≈ $22.31K |
ILA-816.00K ≈ $-2.19K |
-0.098x | +68.46% |
| 2017-12-31 | ILA3.62 Million ≈ $9.70K |
ILA-1.12 Million ≈ $-3.02K |
-0.311x | +51.77% |
| 2016-12-31 | ILA2.69 Million ≈ $7.20K |
ILA-1.73 Million ≈ $-4.64K |
-0.645x | -69.27% |
| 2015-12-31 | ILA4.89 Million ≈ $13.10K |
ILA-1.86 Million ≈ $-4.99K |
-0.381x | +27.86% |
| 2014-12-31 | ILA4.68 Million ≈ $12.54K |
ILA-2.47 Million ≈ $-6.62K |
-0.528x | -43.33% |
| 2013-12-31 | ILA6.79 Million ≈ $18.19K |
ILA-2.50 Million ≈ $-6.70K |
-0.368x | -- |
About XTL Biopharmaceuticals Ltd
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company L… Read more